Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1Dermatologic 1

Conditions

Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 172Rituximab 161Specimen Handling 115Biopsy 92Magnetic Resonance Spectroscopy 90Vincristine 88Doxorubicin 82Prednisone 80fludarabine 71venetoclax 70obinutuzumab 63Lenalidomide 56ibrutinib 55Dexamethasone 55Cytarabine 49Methotrexate 47acalabrutinib 43Etoposide 43CT-P10 41blinatumomab 38fludarabine phosphate 35Bendamustine Hydrochloride 35Gemcitabine 33prednylidene 32zanubrutinib 31deltacortene 31pembrolizumab 30Calcium Dobesilate 30glofitamab 29Nivolumab 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
EPOCH protocol × Lymphoid × 90 days × Clear all
NCT04002947 2026-06-03

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
132 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05996185 2026-04-14

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Yale University

Phase 2 Recruiting
22 enrolled
DermatologicLymphoidOther hematologic neoplasm

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡